Time Works in Favor of DBV's Peanut-Allergy Patch in Study

  • Stock shows steepest gain in six months in Paris trading
  • Skin patch boosts tolerance in 80% of kids after 2 years

DBV Technologies SA’s patch to prevent peanut allergy in children worked better after two years than one and may be effective even after the product is no longer applied to a patient’s skin, the company said.

After two years of treatment with a 250-microgram Viaskin Peanut patch, 80 percent of 21 children experienced a 10-fold increase in tolerance or were able to ingest the equivalent of at least four peanuts, the Bagneux, France-based company said in a statement Monday. That compares with 57 percent after 12 months.

DBV’s shares surged, clocking their biggest gain in six months. They rose 11 percent to 71.04 euros at 9:26 a.m. in Paris. The French company’s stock has gained 61 percent this year, reaching a market value of 1.7 billion euros ($1.9 billion).

“We already know that we have a product that can protect patients after one year and that is absolutely safe,” Chief Operating Officer David Schilansky said in a telephone interview from Bagneux, close to Paris. “Now we’re showing efficacy increases after two years, and after three years, we could see a lasting effect.”

The follow-up data comes from a mid-stage clinical trial known as VIPES. Several companies including California-based Aimmune Therapeutics Inc. are racing to provide the first treatment to protect about 5 percent of U.S. children from a sometimes fatal reaction. DBV Technologies’ patch may fetch a higher price if the company can convince regulators that it’s safer than oral therapy and has a lasting effect on the immune system.

One teenage patient in the VIPES trial continued to be able to tolerate peanuts a year after treatment ended, Schilansky said. DBV has begun the third and final rounding of trials typically needed for regulatory approval. The company aims to enroll 260 patients ages 4 to 11, Schilansky said.

Before it's here, it's on the Bloomberg Terminal.